SUN PHARMA ADV.RES.CO.LTD Valuation

SPARC · Healthcare · Current price ₹201.16

Full stock page
DocStoX fair value
₹1,351
low confidence
Current price
₹201
Upside
+571.8%
P/E ratio
4.2x
P/B ratio
4.7x
Verdict
Strong Buy
Model it yourself — Earnings Yield Calculator
Opens pre-filled with SUN PHARMA ADV.RES.CO.LTD's latest numbers.

Is SUN PHARMA ADV.RES.CO.LTD undervalued?

DocStoX estimates the fair value of SUN PHARMA ADV.RES.CO.LTD at ₹1,351 per share, versus the current market price of ₹201. That puts the stock about +571.8% below our fair-value estimate, which we read as "Strong Buy". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 3 independent methods: Relative P/E (₹1,450), Graham floor (₹210), Analyst target (₹2,040). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹210 (bear) to ₹1,351 (base) to ₹2,040 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Valuation multiples

SUN PHARMA ADV.RES.CO.LTD trades at a P/E of 4.2x and a P/B of 4.7x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.

Understand the ratios

P/E RatioP/B RatioPEG RatioEarnings Yield

More on SUN PHARMA ADV.RES.CO.LTD

Fair ValueIntrinsic ValueDCFFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.